Integrity Alliance LLC. Takes $1.03 Million Position in Bristol Myers Squibb Company $BMY

Key Points

• Integrity Alliance LLC has acquired a new stake in Bristol Myers Squibb Company, purchasing 16,881 shares valued at approximately $1.03 million in the first quarter.
• Wellington Management Group LLP significantly increased its holdings by 297%, while several other institutional investors also made substantial investments in Bristol Myers Squibb in Q1.
• Bristol Myers Squibb recently announced a quarterly dividend of $0.62 per share, representing an annualized dividend yield of 5.2%.

Integrity Alliance LLC. acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 16,881 shares of the biopharmaceutical company's stock, valued at approximately $1,030,000.

Other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP grew its holdings in Bristol Myers Squibb by 297.0% during the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock valued at $1,447,198,000 after purchasing an additional 17,750,938 shares during the period. GQG Partners LLC raised its stake in Bristol Myers Squibb by 22,647.6% during the 1st quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock worth $733,310,000 after acquiring an additional 11,970,598 shares during the period. Nuveen LLC purchased a new position in Bristol Myers Squibb during the first quarter valued at approximately $624,369,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Bristol Myers Squibb by 16.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,271,742 shares of the biopharmaceutical company's stock worth $1,259,690,000 after purchasing an additional 3,196,919 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Bristol Myers Squibb by 7,142.8% during the 1st quarter. GAMMA Investing LLC now owns 2,420,388 shares of the biopharmaceutical company's stock valued at $147,619,000 after purchasing an additional 2,386,970 shares during the period. 76.41% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock traded down $1.32 during midday trading on Friday, reaching $46.22. 11,892,193 shares of the stock traded hands, compared to its average volume of 9,112,865. The stock has a market cap of $94.08 billion, a P/E ratio of 18.64, a PEG ratio of 2.36 and a beta of 0.35. The stock's fifty day moving average is $47.08 and its 200-day moving average is $50.13. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 12 month low of $42.96 and a 12 month high of $63.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company's revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd were issued a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.4%. Bristol Myers Squibb's payout ratio is 100.00%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa Capital Markets lowered Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Citigroup lowered their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a report on Friday, August 1st. Finally, Wall Street Zen lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.